Core Viewpoint - Eton Pharmaceuticals is set to hold a virtual Investor Day on March 18, 2025, to discuss its fourth quarter 2024 financial results and provide insights into its rare disease portfolio and future financial outlook [1][2]. Financial Results and Investor Day - The Investor Day will include a detailed discussion of the fourth quarter 2024 financial results and the company's strategic direction following a transformative six months [2]. - Investors will gain insights into the long-term market opportunities and commercial strategies for the recently acquired Increlex® and Galzin® products [2]. Product Portfolio and Pipeline - Eton currently has seven commercial rare disease products, including INCRELEX®, ALKINDI SPRINKLE®, and GALZIN®, and four additional product candidates in late-stage development, such as ET-400 and ET-600 [4]. - The company will also provide updates on its adrenal insufficiency franchise, including Alkindi Sprinkle® and ET-400, along with the associated market landscape [2]. Event Participation - Interested participants can register for the event, and an archived webcast will be available on Eton's website approximately two hours after the event concludes, remaining accessible for 30 days [3].
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025